Cingulate Stock Today
| CING Stock | USD 4.72 0.07 1.51% |
Performance0 of 100
| Odds Of DistressOver 82
|
Cingulate is trading at 4.72 as of the 25th of November 2024. This is a 1.51 percent increase since the beginning of the trading day. The stock's lowest day price was 4.46. Cingulate has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Cingulate are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of December 2023 and ending today, the 25th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 8th of December 2021 | Category Healthcare | Classification Health Care |
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficithyperactivity disorder. The company was founded in 2012 and is headquartered in Kansas City, Kansas. Cingulate operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 3.21 M outstanding shares of which 89.24 K shares are currently shorted by private and institutional investors with about 0.87 trading days to cover. More on Cingulate
Moving together with Cingulate Stock
Moving against Cingulate Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Cingulate Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO Board | Shane PharmD | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCingulate can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cingulate's financial leverage. It provides some insight into what part of Cingulate's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Cingulate (CING) is traded on NASDAQ Exchange in USA. It is located in 1901 West 47th Place, Kansas City, KS, United States, 66205 and employs 13 people. Cingulate is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 15.16 M. Cingulate conducts business under Biotechnology sector and is part of Health Care industry. The entity has 3.21 M outstanding shares of which 89.24 K shares are currently shorted by private and institutional investors with about 0.87 trading days to cover.
Cingulate currently holds about 8.2 M in cash with (15.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.73.
Check Cingulate Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Cingulate is $15.16 Million. Cingulate shows 3.3 percent of its outstanding shares held by insiders and 2.29 percent owned by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Cingulate Ownership Details
Cingulate Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-09-30 | 0.0 | |
| Jpmorgan Chase & Co | 2024-06-30 | 0.0 | |
| Armistice Capital, Llc | 2024-09-30 | 0.0 | |
| Advisor Group Holdings, Inc. | 2024-06-30 | 0.0 | |
| Hrt Financial Llc | 2024-06-30 | 0.0 | |
| Commonwealth Equity Services Inc | 2024-06-30 | 110.3 K | |
| Bank Of America Corp | 2024-06-30 | 22.5 K | |
| Virtu Financial Llc | 2024-06-30 | 20.2 K | |
| Fmr Inc | 2024-09-30 | 352 | |
| Qube Research & Technologies | 2024-06-30 | 100.0 | |
| Alphamark Advisors, Llc | 2024-09-30 | 10.0 |
Cingulate Historical Income Statement
Cingulate Stock Against Markets
Cingulate Corporate Executives
Elected by the shareholders, the Cingulate's board of directors comprises two types of representatives: Cingulate inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cingulate. The board's role is to monitor Cingulate's management team and ensure that shareholders' interests are well served. Cingulate's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cingulate's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jennifer CPA | Senior CFO | Profile | |
| Dr MBA | Executive COO | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cingulate. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Cingulate Stock please use our How to Invest in Cingulate guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cingulate. If investors know Cingulate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cingulate listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (43.22) | Return On Assets (1.04) | Return On Equity (2.74) |
The market value of Cingulate is measured differently than its book value, which is the value of Cingulate that is recorded on the company's balance sheet. Investors also form their own opinion of Cingulate's value that differs from its market value or its book value, called intrinsic value, which is Cingulate's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cingulate's market value can be influenced by many factors that don't directly affect Cingulate's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cingulate's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cingulate is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cingulate's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.